8 results match your criteria: "1 Green Lane Cardiovascular Service Auckland City Hospital Auckland New Zealand.[Affiliation]"
Longitudinal NT-proBNP: Associations With Echocardiographic Changes and Outcomes in Heart Failure.
J Am Heart Assoc
May 2024
National Heart Research Institute Singapore, National Heart Centre Singapore Singapore.
Article Synopsis
- The study aimed to explore how serial measurements of NT-proBNP, a heart failure biomarker, relate to cardiac changes and patient outcomes, considering various clinical factors.
- Analysis involved 1911 heart failure patients, revealing that NT-proBNP levels generally declined, especially in certain groups like inpatients and those on guideline-recommended medications.
- An increase in NT-proBNP over time was linked to a higher risk of hospitalization or death, with variations noted based on patient age, atrial fibrillation presence, and heart failure types.
Background The plasma concentration of B-type natriuretic peptide (BNP) is a strong predictor of adverse cardiovascular events. The aim of this study was to determine whether the association between plasma BNP concentration and cardiovascular mortality is sustained or diminishes with increasing time after BNP is measured. Methods and Results Six thousand seven hundred forty patients with a history of myocardial infarction or unstable angina who participated in the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) trial had plasma BNP concentration measured at baseline and after 1 year.
View Article and Find Full Text PDFBackground: We meta-analyzed the efficacy and safety of catheter (CA) vs thoracoscopic (TA) ablation for atrial fibrillation (AF).
Methods: PubMed, Embase, and Cochrane databases were searched until 31/12/2019 for relevant randomized trials and subsequent pooled analyses.
Results: In six trials totaling 465 patients (254 CA/211 TA), 1-year AF recurrences were higher for CA (46% vs 26%, odds ratio 2.
Background: Vascular complications are common during invasive cardiac electrophysiology procedures. This meta-analysis compares outcomes following ultrasound and nonultrasound-guided vascular access for these procedures.
Methods: PubMed, Embase and Cochrane 01/01/1980-30/09/2018 were searched for relevant studies to meta-analyse.
Article Synopsis
- A study assessed cognitive performance using the Montreal Cognitive Assessment in 10,634 patients with coronary heart disease, comparing those treated with darapladib and those given a placebo, finding no significant difference in scores between the two groups.
- Factors like age, education level, and cardiovascular risk factors (e.g., history of stroke, low exercise, poor cholesterol levels) were found to significantly affect the likelihood of mild cognitive impairment among participants.
- The results indicated that while cognitive performance was linked to modifiable cardiovascular risk factors and education, it was not influenced by the darapladib treatment.
Background: Cardiac resynchronization therapy (CRT) has been shown to improve morbidity and mortality for heart failure (HF) patients. Little is known about the trends in CRT use and outcomes of these patients in New Zealand.
Method: Mortality, hospitalization events and complications in HF patients in the Northern Region of New Zealand implanted with CRT devices from Jan-2007 to June-2015 were reviewed.
Background Vorapaxar, a protease-activated receptor-1 antagonist, is approved for secondary prevention of cardiovascular events but is associated with increased intracranial hemorrhage. Methods and Results TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) was a trial of vorapaxar versus placebo among patients with acute coronary syndrome. Strokes were adjudicated by a central events committee.
View Article and Find Full Text PDFBackground: Implantable cardioverter-defibrillator (ICD) therapy is indicated for selected heart failure patients for the primary prevention of sudden cardiac death. Little is known about the outcomes in patients selected for primary prevention device therapy in the northern region of New Zealand.
Method: Heart failure patients with systolic dysfunction who underwent primary prevention ICD/cardiac resynchronization therapy-defibrillator (CRT-D) implantation between January 1, 2007, and June 1, 2015, were included.